Telemedically augmented palliative care: Empowerment for patients with non-small cell lung cancer and their family caregivers
- Conditions
- C34Malignant neoplasm of bronchus and lung
- Registration Number
- DRKS00004899
- Lead Sponsor
- Medizinische Universität Wien
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
PATIENTS:
•Patients of each sex between 18 and 75 years
•Patients with histologically or cytologically confirmed incurable NSCLC, stage IV
•Inclusion has to be before the first chemotherapy is received
•Patients with an ECOG performance status of 0, 1 or 2 (with 0 indicating that the patient is asymptomatic, 1 that the patient is symptomatic but fully ambulatory, and 2 that the patient is symptomatic and in bed <50 % of the day)
•Patients without cognitive impairment
FAMILY CAREGIVERS:
(for every patient, one of his/her caregivers will be included)
•Family caregivers without cognitive impairment
PATIENTS:
•All patients without signed informed consent (including persons unable to give consent)
•Patients with prior chemotherapy for metastatic disease
•Patients with ECOG > 2
•Patients with cognitive impairment
FAMILY CAREGIVERS:
•Family caregivers without signed informed consent (including persons unable to give consent)
•Family caregivers with cognitive impairment
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improve patients’ and family caregivers’ quality of life via validated questionnaires (HADS, FAMCARE, EORTC<br>QLQ--C15--PAL) at three different points of time: baseline (recruitment), 10 weeks after baseline, 20 weeks after baseline.
- Secondary Outcome Measures
Name Time Method umber of hospital admissions and emergency room visits during study period (1 year or until death of the patient).
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.